首页> 美国卫生研究院文献>Oncology Letters >Japanese apricot extract (MK615) potentiates bendamustine-induced apoptosis via impairment of the DNA damage response in lymphoma cells
【2h】

Japanese apricot extract (MK615) potentiates bendamustine-induced apoptosis via impairment of the DNA damage response in lymphoma cells

机译:日本杏提取物(MK615)通过损害淋巴瘤细胞的DNA损伤反应来增强苯达莫司汀诱导的细胞凋亡

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Bendamustine, a hybrid molecule of a purine analog and alkylator, induces cell death by the activation of apoptosis and the DNA damage response. The agent MK615 is produced from Japanese apricot and contains a number of cyclic triterpenes that exhibit antitumor activities. In the present study, the combined effects of bendamustine and MK615 on lymphoma cells were investigated. The combined compounds synergistically induced apoptosis in all lymphoid cell lines examined. MK615 inhibited the bendamustine-induced phosphorylation of checkpoint kinase 1 and 2. As ataxia telangiectasia mutated (ATM) and ataxia telangiectasia- and Rad3-related (ATR) kinases are key mediators of the DNA damage response, the effects of the combination of bendamustine and ATM/ATR inhibitors (KU-60019 and VE-821) on lymphoma cells were investigated. KU-60019 and/or VE-821 potentiated bendamustine activity in all cell lines tested, but did not affect MK615 activity, suggesting that these inhibitors have the same underlying mechanism of action as that of MK615. The results of the present study suggest that it may be feasible to use ATM/ATR inhibitors in combination with bendamustine for treating malignant lymphoma.
机译:苯达莫司汀是嘌呤类似物和烷基化剂的杂合分子,通过激活细胞凋亡和DNA损伤反应来诱导细胞死亡。试剂MK615由日本杏生产,并含有许多具有抗肿瘤活性的环状三萜。在本研究中,研究了苯达莫司汀和MK615对淋巴瘤细胞的联合作用。组合的化合物在所有检查的淋巴样细胞系中协同诱导凋亡。 MK615抑制苯达莫司汀诱导的检查点激酶1和2的磷酸化。共济失调毛细血管扩张(ATM)和共济失调毛细血管扩张及Rad3相关(ATR)激酶是DNA损伤反应的主要介质,苯达莫司汀和研究了淋巴瘤细胞上的ATM / ATR抑制剂(KU-60019和VE-821)。 KU-60019和/或VE-821在所有测试的细胞系中增强了苯达莫司汀活性,但不影响MK615活性,表明这些抑制剂具有与MK615相同的基本作用机理。本研究的结果表明,将ATM / ATR抑制剂与苯达莫司汀联用治疗恶性淋巴瘤可能是可行的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号